Windtree receives Nasdaq delisting notices for board independence and bid price deficiencies

WINDTREE THERAPEUTICS INC /DE/

CEO appointment Jed Latkin (former independent director) on Dec 1, 2024 caused loss of majority independent board and audit committee shortfall.
Non-compliance with Nasdaq Rules 5605(b)(1) and 5605(c)(2)(A); cure period until Dec 1, 2025 or next annual meeting.
Bid price deficiency: closing bid below $1.00 for 30 consecutive days; ineligible for 180-day grace due to two reverse stock splits (cumulative >250:1) in prior 2 years.
Company intends to request a hearing before Nasdaq Hearings Panel to stay delisting; no assurance of regaining compliance.
Common stock continues trading on Nasdaq under symbol WINT; delisting risk remains if compliance not restored.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.